# US 2026/0091031 A1 · Cgrp receptor antagonists for treating chemotherapy-induced nausea and vomiting (cinv)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0091031 A1
- Document ID: US20260091031A1
- Status: Published application
- Kind: A1
- Application number: 19/111,786
- Filed: 2023-09-13
- Published: 2026-04-02
- Earliest claimed: 2022-09-14
- Inventors: Alberto CHIARUGI
- Web page: https://patentgrep.com/patent/US20260091031A1

## CPC

- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 33/243: Platinum; Compounds thereof
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method in which gepants (antagonists of calcitonin gene related peptide (CGRP) receptor) are used for direct treatment of nausea and vomiting including chemotherapy-induced nausea and vomiting (CINV). Among them, drugs frequently prompt nausea and vomiting, such as antitumor chemotherapeutics which often cause CINV which in turn can severely compromise efficacy of therapy, as well as patient quality of life. The method uses antagonists of the CGRP receptor recently approved for migraine treatment to target calcitonin gene related peptide (CGRP), a neuropeptide with pleiotypic effects in the human body to prevent and counteract drug-induced nausea and vomiting including CINV.

## Claims

### Claim 1

A method for prevention of chemotherapy-induced nausea and vomiting (CINV) in an individual in need, the method comprising
administering an effective amount of an antagonist of a CGRP receptor or a pharmaceutically acceptable formulation thereof to the individual in need, to the prevent chemotherapy-induced nausea and vomiting (CINV) in the individual.

### Claim 2

A method for treating chemotherapy-induced nausea and vomiting (CINV) in an individual in need, the method comprising
administering an effective amount of an antagonist of a CGRP receptor and or a pharmaceutically acceptable formulation thereof to the individual in need, to treat chemotherapy-induced nausea and vomiting (CINV) in the individual.

### Claim 3

A method for prevention or treatment of chemotherapy-induced nausea and vomiting (CINV) in an individual in need, the method comprising administering an effective amount of an antagonist of a CGRP receptor and or a pharmaceutically acceptable formulation thereof to the individual in need, to potentiate the effect of drugs used to prevent or treat chemotherapy-induced nausea and vomiting in the individual.

### Claim at position 4

-6. (canceled)

### Claim 7 (depends on 1)

The method of claim 1, wherein case said antagonist is Rimegepant.

### Claim 8 (depends on 1)

The method of claim 1, wherein said antagonist is Ubrogepant.

### Claim 9 (depends on 1)

The method of claim 1, wherein said antagonist is Atogepant.

### Claim 10 (depends on 1)

The method of claim 1, wherein said antagonist is Zavegepant.

### Claim 11 (depends on 2)

The method of claim 2, wherein said antagonist is Rimegepant.

### Claim 12 (depends on 2)

The method of claim 2, wherein said antagonist is Ubrogepant.

### Claim 13 (depends on 2)

The method of claim 2, wherein said antagonist is Atogepant.

### Claim 14 (depends on 2)

The method of claim 2, wherein said antagonist is Zavegepant.

### Claim 15 (depends on 3)

The method of claim 3, wherein said antagonist is Rimegepant.

### Claim 16 (depends on 3)

The method of claim 3, wherein said antagonist is Ubrogepant.

### Claim 17 (depends on 3)

The method of claim 3, wherein said antagonist is Atogepant.

### Claim 18 (depends on 3)

The method of claim 3, wherein said antagonist is Zavegepant.